Matches in SemOpenAlex for { <https://semopenalex.org/work/W1978315037> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W1978315037 abstract "Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CASmall molecule kinase inhibitors have opened potential new avenues for treating cancers dependent on the RAS-RAF-MEK-ERK MAPK pathway, yet identification of both de novo/innate/intrinsic and acquired resistance mechanisms will be critical for the successful application of these inhibitors in the clinic. We interrogated the kinome to identify resistance mechanisms towards the novel ERK1/2-selective inhibitor SCH772984. We first utilized a kinome-focused RNAi screen to identify genes that, when silenced, sensitized KRAS-dependent pancreatic cancer cells to SCH772984. In our drug dose-response screen of 711 kinases (QIAGEN library), we used 4 independent siRNA duplexes to knock down each gene, treated at 5 different drug doses, then evaluated viability with a standard CellTiter-Glo assay. Nineteen kinases enhanced sensitivity to SCH772984 (where at least 2 siRNAs for each target decreased IC50) at least 5-fold, indicating that they could drive ERK1/2 inhibitor resistance. Among these were 4 of the 9 protein kinases (Cot, Raf-1, PAK3 and PRKCH) identified in a cDNA expression screen for kinases that caused resistance of BRAF-mutant melanoma to the BRAF inhibitor vemurafenib. We therefore hypothesized that at least some of the kinases that scored positive in this screen might be conserved both across the MAPK pathway and across different cancer types. The tetrameric protein kinase CK2 (formerly casein kinase II) has crucial roles in cell survival, proliferation and differentiation, and its expression and/or activity is dysregulated in cancers including melanoma. In very recent studies, we have now determined that the alpha subunit of CK2 is sufficient to cause resistance to each of the three ERK MAPK pathway inhibitors currently approved for treatment of melanoma: vemurafenib (BRAFi), dabrafenib (BRAFi) and trametinib (MEKi). Co-inhibition of the MAPK pathway and CK2 (e.g., with CX-4945, currently in phase I trials) further enhanced sensitivity. Thus, this combination may offer an effective regimen to forestall or delay tumor relapse. We also observed that CK2alpha maintains ERK phosphorylation in the presence of MAPK inhibitors, and that it posttranslationally reduces abundance of the ERK phosphatase DUSP6/MKP-3, in a kinase-dependent manner. The relationship of these findings to CK2-mediated mechanisms of drug resistance will be discussed.Citation Format: Bingying Zhou, Michelle Kassner, Holly Yin, Channing J. Der, Adrienne D. Cox. CK2 protein kinase promotes resistance to MAPK pathway inhibition. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr LB-217. doi:10.1158/1538-7445.AM2014-LB-217" @default.
- W1978315037 created "2016-06-24" @default.
- W1978315037 creator A5013297528 @default.
- W1978315037 creator A5024561763 @default.
- W1978315037 creator A5054263237 @default.
- W1978315037 creator A5057108733 @default.
- W1978315037 creator A5064063895 @default.
- W1978315037 date "2014-09-30" @default.
- W1978315037 modified "2023-09-25" @default.
- W1978315037 title "Abstract LB-217: CK2 protein kinase promotes resistance to MAPK pathway inhibition" @default.
- W1978315037 doi "https://doi.org/10.1158/1538-7445.am2014-lb-217" @default.
- W1978315037 hasPublicationYear "2014" @default.
- W1978315037 type Work @default.
- W1978315037 sameAs 1978315037 @default.
- W1978315037 citedByCount "0" @default.
- W1978315037 crossrefType "proceedings-article" @default.
- W1978315037 hasAuthorship W1978315037A5013297528 @default.
- W1978315037 hasAuthorship W1978315037A5024561763 @default.
- W1978315037 hasAuthorship W1978315037A5054263237 @default.
- W1978315037 hasAuthorship W1978315037A5057108733 @default.
- W1978315037 hasAuthorship W1978315037A5064063895 @default.
- W1978315037 hasConcept C104317684 @default.
- W1978315037 hasConcept C121608353 @default.
- W1978315037 hasConcept C166703698 @default.
- W1978315037 hasConcept C184235292 @default.
- W1978315037 hasConcept C22615655 @default.
- W1978315037 hasConcept C2776131300 @default.
- W1978315037 hasConcept C2777658100 @default.
- W1978315037 hasConcept C2781187634 @default.
- W1978315037 hasConcept C2994587330 @default.
- W1978315037 hasConcept C502942594 @default.
- W1978315037 hasConcept C526805850 @default.
- W1978315037 hasConcept C54009773 @default.
- W1978315037 hasConcept C54174078 @default.
- W1978315037 hasConcept C54355233 @default.
- W1978315037 hasConcept C55493867 @default.
- W1978315037 hasConcept C57074206 @default.
- W1978315037 hasConcept C67705224 @default.
- W1978315037 hasConcept C86803240 @default.
- W1978315037 hasConcept C95444343 @default.
- W1978315037 hasConcept C97029542 @default.
- W1978315037 hasConcept C98274493 @default.
- W1978315037 hasConceptScore W1978315037C104317684 @default.
- W1978315037 hasConceptScore W1978315037C121608353 @default.
- W1978315037 hasConceptScore W1978315037C166703698 @default.
- W1978315037 hasConceptScore W1978315037C184235292 @default.
- W1978315037 hasConceptScore W1978315037C22615655 @default.
- W1978315037 hasConceptScore W1978315037C2776131300 @default.
- W1978315037 hasConceptScore W1978315037C2777658100 @default.
- W1978315037 hasConceptScore W1978315037C2781187634 @default.
- W1978315037 hasConceptScore W1978315037C2994587330 @default.
- W1978315037 hasConceptScore W1978315037C502942594 @default.
- W1978315037 hasConceptScore W1978315037C526805850 @default.
- W1978315037 hasConceptScore W1978315037C54009773 @default.
- W1978315037 hasConceptScore W1978315037C54174078 @default.
- W1978315037 hasConceptScore W1978315037C54355233 @default.
- W1978315037 hasConceptScore W1978315037C55493867 @default.
- W1978315037 hasConceptScore W1978315037C57074206 @default.
- W1978315037 hasConceptScore W1978315037C67705224 @default.
- W1978315037 hasConceptScore W1978315037C86803240 @default.
- W1978315037 hasConceptScore W1978315037C95444343 @default.
- W1978315037 hasConceptScore W1978315037C97029542 @default.
- W1978315037 hasConceptScore W1978315037C98274493 @default.
- W1978315037 hasLocation W19783150371 @default.
- W1978315037 hasOpenAccess W1978315037 @default.
- W1978315037 hasPrimaryLocation W19783150371 @default.
- W1978315037 hasRelatedWork W1968014303 @default.
- W1978315037 hasRelatedWork W1993646859 @default.
- W1978315037 hasRelatedWork W1996349796 @default.
- W1978315037 hasRelatedWork W2028499791 @default.
- W1978315037 hasRelatedWork W2077914269 @default.
- W1978315037 hasRelatedWork W2321300947 @default.
- W1978315037 hasRelatedWork W2472419401 @default.
- W1978315037 hasRelatedWork W2599780992 @default.
- W1978315037 hasRelatedWork W2741304831 @default.
- W1978315037 hasRelatedWork W2741862198 @default.
- W1978315037 hasRelatedWork W2918395562 @default.
- W1978315037 hasRelatedWork W2948938180 @default.
- W1978315037 hasRelatedWork W2953959455 @default.
- W1978315037 hasRelatedWork W2955071179 @default.
- W1978315037 hasRelatedWork W3022083945 @default.
- W1978315037 hasRelatedWork W3023781015 @default.
- W1978315037 hasRelatedWork W3081793128 @default.
- W1978315037 hasRelatedWork W3082375249 @default.
- W1978315037 hasRelatedWork W3082426365 @default.
- W1978315037 hasRelatedWork W3205450755 @default.
- W1978315037 isParatext "false" @default.
- W1978315037 isRetracted "false" @default.
- W1978315037 magId "1978315037" @default.
- W1978315037 workType "article" @default.